ArQule to Present at the 20th Annual Global Investment Conference on September 5, 2018
August 29 2018 - 4:01PM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci,
Chief Executive Officer, and Marc Schegerin, Senior Vice President,
Strategy, Communication and Finance, will present at the 20th
Annual Rodman & Renshaw Global Investment Conference, sponsored
by H.C. Wainwright & Co., LLC, on September 5, 2018, at 12:05pm
ET at the St. Regis New York Hotel in New York City.
The live webcast of the presentation will be available via the
“Investors & Media” section of ArQule’s website,
www.arqule.com, under “Events & Presentations.” A replay of the
webcast will be available shortly after the conclusion of the
presentation.
About ArQule
ArQule is a biopharmaceutical company engaged in the research
and development of targeted therapeutics to treat cancers and rare
diseases. ArQule’s mission is to discover, develop and
commercialize novel small molecule drugs in areas of high unmet
need that will dramatically extend and improve the lives of our
patients. Our clinical-stage pipeline consists of five drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s pipeline includes: ARQ 531, an orally
bioavailable, potent and reversible inhibitor of both wild type and
C481S-mutant BTK, in Phase 1 for patients with B-cell malignancies
refractory to other therapeutic options; Miransertib (ARQ 092), a
selective inhibitor of the AKT serine/threonine kinase, in a Phase
1/2 company-sponsored study for Overgrowth Diseases, in a Phase 1
study for ultra-rare Proteus syndrome conducted by the National
Institutes of Health (NIH), and in Phase 1b in combination with the
hormonal therapy, anastrozole, in patients with advanced
endometrial cancer; ARQ 751, a next generation AKT inhibitor, in
Phase 1 for patients with AKT1 and PI3K mutations; Derazantinib, a
multi-kinase inhibitor designed to preferentially inhibit the
fibroblast growth factor receptor (FGFR) family, in a
registrational trial for iCCA; and ARQ 761, a β-lapachone analog
being evaluated as a promoter of NQO1-mediated programmed cancer
cell necrosis, in Phase 1/2 in multiple oncology indications in
partnership with the University of Texas Southwestern Medical
Center. ArQule’s current discovery efforts are focused on the
identification and development of novel kinase inhibitors,
leveraging the Company’s proprietary library of compounds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180829005497/en/
Corporate Contact:ArQule, Inc.Marc Schegerin, M.D.Senior
Vice President, Strategy, Communication and
Financeir@arqule.comorMedia Contact:LifeSci Public
RelationsAllison Blum, Ph.D.,
646-627-8383Allison@lifescipublicrelations.comwww.ArQule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Aug 2024 to Sep 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Sep 2023 to Sep 2024